deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03990454

Safety Study of SLC-391 in Subjects With Solid Tumors

A Phase 1, Open-label, Dose-escalationStudy of the Safety and Pharmacokinetics of the AXL Inhibitor SLC-391 Administered Orally to Subjects With Solid Tumours

Sponsor: SignalChem Lifesciences Corporation

Conditions Solid Tumor
Interventions SLC-391
Updated 13 times since 2019 Last updated: Aug 16, 2023 Started: Sep 17, 2019 Primary completion: Jun 30, 2023 Completion: Jun 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Solid Tumor, this trial is completed. The trial is conducted by SignalChem Lifesciences Corporation and has accumulated 13 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~Nov 2020 · 7 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2022 · 15 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Recruiting → Completed

  4. Apr 2023 — Sep 2023 [monthly]

    Recruiting PHASE1

  5. Sep 2022 — Apr 2023 [monthly]

    Recruiting PHASE1

▶ Show 8 earlier versions

  1. Jun 2021 — Sep 2022 [monthly]

    Recruiting PHASE1

  2. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE1

  3. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  4. Apr 2020 — Nov 2020 [monthly]

    Recruiting PHASE1

  5. Feb 2020 — Apr 2020 [monthly]

    Recruiting PHASE1

  6. Nov 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  7. Sep 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE1

  8. Jul 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • SignalChem Lifesciences Corporation
Data source: SignalChem Lifesciences Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations